CORBUS PHARMACEUTICALS HOLDI (CRBP) Stock Analyst Ratings
NASDAQ:CRBP • US21833P3010
8.21 USD
-0.14 (-1.68%)
At close: Mar 3, 2026
8.21 USD
0 (0%)
After Hours: 3/3/2026, 4:30:02 PM
ChartMill assigns a Buy % Consensus number of 86% to CRBP. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 43.18. This target is 425.94% above the current price.
- CRBP was analyzed by 16 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about CRBP.
- In the previous month the buy percentage consensus was at a similar level.
- CRBP was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-13 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-20 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-10-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-07 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-11 | Jefferies | Maintains | Buy -> Buy |
| 2025-02-28 | William Blair | Initiate | Outperform |
| 2025-02-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-02 | Piper Sandler | Initiate | Overweight |
| 2024-09-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-20 | Mizuho | Reiterate | Outperform -> Outperform |
| 2024-09-20 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-09-20 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-09-20 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-08-28 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-07 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-08-07 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-22 | HC Wainwright & Co. | Reiterate | Buy |
| 2024-07-10 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-06-26 | B. Riley Securities | Initiate | Buy |
| 2024-06-11 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-06-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-05-13 | RBC Capital | Initiate | Outperform |
| 2024-05-08 | Oppenheimer | Maintains | Outperform -> Outperform |
CORBUS PHARMACEUTICALS HOLDI / CRBP FAQ
What is the average price target for CORBUS PHARMACEUTICALS HOLDI (CRBP) stock?
16 analysts have analysed CRBP and the average price target is 43.18 USD. This implies a price increase of 425.94% is expected in the next year compared to the current price of 8.21.
How do analysts rate CORBUS PHARMACEUTICALS HOLDI (CRBP)?
The consensus rating for CORBUS PHARMACEUTICALS HOLDI (CRBP) is 86.25 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for CORBUS PHARMACEUTICALS HOLDI stock?
The number of analysts covering CORBUS PHARMACEUTICALS HOLDI (CRBP) is 16.